Semaglutide linked to fewer asthma and COPD attacks in study

Questions about this coverage

How did the left and right cover Semaglutide linked to fewer asthma and COPD attacks in study?

Of the 60 outlets on this story carrying a published leaning rating, 18% are rated left, 69% are rated centre, 13% are rated right. Those percentages are shares of the rated outlets, not of every outlet that ran it, which was 67. The sections above set out what each side emphasised, in its own terms.

Is Semaglutide linked to fewer asthma and COPD attacks in study left or right?

Neither side dominates it. Of the 60 rated outlets on this story, 18% are rated left, 69% are rated centre, 13% are rated right, and no side holds the 70% this site would want before calling a field one-sided. A story is not left or right in any case; the outlets that carried it are what carry ratings.

Is the coverage of Semaglutide linked to fewer asthma and COPD attacks in study biased?

Semaglutide linked to fewer asthma and COPD attacks in study is one event reported by 67 outlets, and this page does not rate the story as biased or unbiased. What it publishes is the spread: which outlets ran it, where named rating organisations place each of them on the spectrum, and what each side chose to lead with. A leaning rating describes an outlet's record over time, not this article, and the two should not be run together.

Which outlets covered Semaglutide linked to fewer asthma and COPD attacks in study?

67 that we know of, every one of them listed further up this page with a link to its own report and to what we hold on the publisher. Nothing here is a summary of somebody else's summary: the outlets are named so the original reporting can be read.

What did the study find about semaglutide and asthma attacks?

A study presented at the European Respiratory Society Congress found that semaglutide, the active ingredient in Ozempic and Wegovy, was linked to a nearly 40% reduction in asthma attacks. It was also associated with a 20% decrease in COPD flare-ups.

Who conducted the study and where were the records from?

The study was conducted by British scientists who examined UK medical records from tens of thousands of people taking GLP-1 drugs. Professor Chloe Bloom from Imperial College London was a study author.

Can semaglutide be used to treat asthma or COPD?

Scientists believe the anti-inflammatory properties of GLP-1 drugs may explain the respiratory benefits, but the study cannot prove causation. Researchers stressed that further clinical trials are needed before GLP-1 drugs could be considered a treatment for lung conditions.